ES2535040T3 - Forma cocristalina "A" con metilparaben de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((S)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona - Google Patents

Forma cocristalina "A" con metilparaben de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((S)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona Download PDF

Info

Publication number
ES2535040T3
ES2535040T3 ES07857734.3T ES07857734T ES2535040T3 ES 2535040 T3 ES2535040 T3 ES 2535040T3 ES 07857734 T ES07857734 T ES 07857734T ES 2535040 T3 ES2535040 T3 ES 2535040T3
Authority
ES
Spain
Prior art keywords
trifluor
methyl
piperazin
methanesulfonyl
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07857734.3T
Other languages
English (en)
Spanish (es)
Inventor
André BUBENDORF
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Emmanuel Pinard
Franziska E. Rohrer
Urs Schwitter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2535040(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2535040T3 publication Critical patent/ES2535040T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ES07857734.3T 2006-12-28 2007-12-18 Forma cocristalina "A" con metilparaben de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((S)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona Active ES2535040T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28
EP06127269 2006-12-28
PCT/EP2007/064104 WO2008080821A1 (en) 2006-12-28 2007-12-18 Crystalline forms glyt1

Publications (1)

Publication Number Publication Date
ES2535040T3 true ES2535040T3 (es) 2015-05-04

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07857734.3T Active ES2535040T3 (es) 2006-12-28 2007-12-18 Forma cocristalina "A" con metilparaben de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((S)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona

Country Status (33)

Country Link
US (5) US20080214561A1 (https=)
EP (1) EP2114405B1 (https=)
JP (1) JP4799666B2 (https=)
KR (1) KR101130146B1 (https=)
CN (1) CN101573114A (https=)
AR (1) AR064545A1 (https=)
AU (1) AU2007341356B2 (https=)
BR (1) BRPI0720829B8 (https=)
CA (1) CA2673667A1 (https=)
CL (1) CL2007003830A1 (https=)
CO (1) CO6190613A2 (https=)
CR (1) CR10846A (https=)
CY (1) CY1116350T1 (https=)
DK (1) DK2114405T3 (https=)
EC (1) ECSP099471A (https=)
ES (1) ES2535040T3 (https=)
HR (1) HRP20150573T1 (https=)
HU (1) HUE025032T2 (https=)
MA (1) MA31029B1 (https=)
MX (1) MX2009006859A (https=)
MY (1) MY188367A (https=)
NO (1) NO342150B1 (https=)
NZ (1) NZ577502A (https=)
PE (1) PE20081556A1 (https=)
PL (1) PL2114405T3 (https=)
PT (1) PT2114405E (https=)
RS (1) RS53910B1 (https=)
RU (1) RU2463295C2 (https=)
SI (1) SI2114405T1 (https=)
TW (1) TWI388552B (https=)
UA (1) UA100232C2 (https=)
WO (1) WO2008080821A1 (https=)
ZA (1) ZA200904423B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006859A (es) 2006-12-28 2009-07-03 Hoffmann La Roche Formas cristalinas de glyt1.
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
CN104334550A (zh) * 2012-05-25 2015-02-04 巴斯夫欧洲公司 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
JP7096956B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
EP4337199A4 (en) * 2021-05-14 2025-03-19 Disc Medicine, Inc. Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents
CN118043050A (zh) * 2021-05-27 2024-05-14 迪斯克医药公司 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
MX2009006859A (es) 2006-12-28 2009-07-03 Hoffmann La Roche Formas cristalinas de glyt1.

Also Published As

Publication number Publication date
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
US20120309969A1 (en) 2012-12-06
NO342150B1 (no) 2018-04-03
CY1116350T1 (el) 2017-03-15
AU2007341356A1 (en) 2008-07-10
HUE025032T2 (en) 2016-02-29
JP2010514725A (ja) 2010-05-06
NZ577502A (en) 2012-02-24
BRPI0720829B8 (pt) 2021-05-25
TW200833677A (en) 2008-08-16
UA100232C2 (uk) 2012-12-10
US20080214561A1 (en) 2008-09-04
MA31029B1 (fr) 2009-12-01
KR20090094166A (ko) 2009-09-03
CN101573114A (zh) 2009-11-04
US20130197225A1 (en) 2013-08-01
SI2114405T1 (sl) 2015-06-30
PE20081556A1 (es) 2008-11-28
ZA200904423B (en) 2010-05-26
US20110295007A1 (en) 2011-12-01
BRPI0720829B1 (pt) 2020-04-07
DK2114405T3 (en) 2015-04-07
PL2114405T3 (pl) 2015-08-31
US20100311971A1 (en) 2010-12-09
MY188367A (en) 2021-12-06
MX2009006859A (es) 2009-07-03
CO6190613A2 (es) 2010-08-19
CR10846A (es) 2009-08-12
CA2673667A1 (en) 2008-07-10
RU2009124113A (ru) 2011-02-10
KR101130146B1 (ko) 2012-03-28
HRP20150573T1 (xx) 2015-07-03
RU2463295C2 (ru) 2012-10-10
WO2008080821A1 (en) 2008-07-10
ECSP099471A (es) 2009-07-31
NO20092358L (no) 2009-06-22
PT2114405E (pt) 2015-06-02
AR064545A1 (es) 2009-04-08
EP2114405B1 (en) 2015-03-11
US8039473B2 (en) 2011-10-18
TWI388552B (zh) 2013-03-11
RS53910B1 (sr) 2015-08-31
JP4799666B2 (ja) 2011-10-26
BRPI0720829A2 (pt) 2014-02-25
CL2007003830A1 (es) 2008-07-11

Similar Documents

Publication Publication Date Title
ES2535040T3 (es) Forma cocristalina "A" con metilparaben de la [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((S)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona
ES2639052T3 (es) Forma polimórfica de hidrocloruro de pridopidina
ES2577391T3 (es) Polimorfos de un antagonista del receptor mglur5
CN105263917B (zh) 新abexinostate盐、相关的晶体形式、其制备方法以及含有其的药物组合物
TW202124373A (zh) 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法
KR102566383B1 (ko) 3-하이드록시-비스-벤질옥시-6-벤질옥시메틸-2-페닐-2-옥소-2λ5-[1,2]옥사포스피난의 결정질 다형 형태
ES2539236T3 (es) Sal de ácido benzoico de Otamixaban
HK1136207A (en) Crystalline forms glyt1
BR112021013035A2 (pt) Complexo molecular de binimetinibe, processo para preparar solvato de dmso de binimetinibe, complexo molecular, processo para preparar um complexo molecular cristalino de binimetinibe e ácido cítrico, composição farmacêutica, método para inibir a atividade de mek, e, método para o tratamento de um distúrbio hiperproliferativo.
BRPI0720954B1 (pt) Forma cristalina do sal de monossulfato de um antagonista de receptor mglur5, seu uso, processo de preparação do mesmo e composição farmacêutica que o compreende
CN108864100A (zh) 一种巯嘌呤与二甲双胍的盐、其制备方法及晶体结构
HK1199728B (en) Polymorphic form of pridopidine hydrochloride
HK1220965B (en) Novel abexinostat salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
NZ623344B2 (en) Polymorphic form of pridopidine hydrochloride